Abstract:In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell（TCR-T） therapy and chimeric antigen receptor T cell（CAR-T） therapy. Due to their structure difference, TCR-T and CAR-T cells show different characteristics in signal activation and antigen recognition. CAR has scFv derived from antibody, containing CD3ζ and costimulatory domain（s）, making engineered CAR able to recognize specific tumor associated antigens. Therefore, CAR has an ability to bind unprocessed tumor surface antigens without MHC processing, while TCR engages with both tumor intracellular and surface antigens embedded in MHC. While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. Even though clinical results are encouraging for both approaches, several major challenges have been identified, including: target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into the tumor, T cell persistence, and local immunosuppression in the tumor microenvironment. Synthetic biology technologies have enabled flexible reprogramming of engineered T cells to overcome the aforementioned limitations, bringing new opportunities for improving their safety and effectiveness, but the choice of a suitable target antigen is still a key for success. Moreover, improved preclinical TCR/CAR screening is likely to enhance the safety of engineered T cell therapies, and additional T cell engineering to further enhance engineered T cells at various levels has generated promising results, including:（1） modulation of affinity,（2） safety control elements, and（3） targeting TME components. Future developments will likely harness combinatorial strategies to overcome challenges posed by the tumors. In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy.

Exploiting T cell signaling to optimize engineered T cell therapies

Genetically engineered T cells for cancer immunotherapy

Synthetic biology and engineered T cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

[Advances in Structural Designs of Chimeric Antigen Receptor T Cells--Review].

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

The signaling and the metabolic differences of various CAR T cell designs

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Emerging Strategies in TCR-Engineered T Cells

From TCR fundamental research to innovative chimeric antigen receptor design

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy

Targeting cancers through TCR-peptide/MHC interactions

From Therapeutic Antibodies to Chimeric Antigen Receptors (cars): Making Better CARs Based on Antigen-Binding Domain

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR-T design: Elements and their synergistic function

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Optimization of T Cell Redirecting Strategies: Obtaining Inspirations from Natural Process of T Cell Activation

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects